{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:31:18Z","timestamp":1772753478595,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.coph.2015.11.007","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T22:58:41Z","timestamp":1449788321000},"page":"67-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Integrins and adhesion molecules as targets to treat inflammatory bowel disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Ivana","family":"Bravat\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Allocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2015.11.007_bib0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(08)60995-2","article-title":"Crohn's disease: beyond antagonists of tumour necrosis factor","volume":"372","author":"Peyrin-Biroulet","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2015.11.007_bib0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","article-title":"Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health","volume":"61","author":"Peyrin-Biroulet","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.coph.2015.11.007_bib0125","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/ajg.2013.53","article-title":"Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature","volume":"108","author":"Peyrin-Biroulet","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2015.11.007_bib0130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.MIB.0000225339.91484.fc","article-title":"Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study)","volume":"12","author":"Henriksen","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2015.11.007_bib0135","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2015.11.007_bib0140","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2015.11.007_bib0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2015.11.007_bib0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1756283X14558193","article-title":"Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases","volume":"8","author":"Amiot","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.coph.2015.11.007_bib0155","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1440-1746.2010.06407.x","article-title":"Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience","volume":"25","author":"Lawrance","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2015.11.007_bib0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2015.11.007_bib0165","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gut.2008.163667","article-title":"Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease","volume":"58","author":"Brand","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.coph.2015.11.007_bib0170","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","article-title":"Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases","volume":"140","author":"Strober","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2015.11.007_bib0175","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2015.11.007_bib0180","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2015.11.007_sbref0185","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2015.11.007_bib0190","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2015.11.007_sbref0195","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2015.11.007_bib0200","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1476-5381.2011.01205.x","article-title":"A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes","volume":"162","author":"Stefanich","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2015.11.007_sbref0205","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.coph.2015.11.007_sbref0210","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2015.11.007_sbref0215","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bcp.12418","article-title":"Clinical pharmacology of AMG 181, a gut-specific human anti-alpha4beta7 monoclonal antibody, for treating inflammatory bowel diseases","volume":"78","author":"Pan","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2015.11.007_bib0220","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489215001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489215001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:48:24Z","timestamp":1761461304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489215001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":22,"alternative-id":["S1471489215001459"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2015.11.007","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrins and adhesion molecules as targets to treat inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2015.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}